Evidence map›Paper›PMID 40620890›Full record

ArticleContemporary oncology (Poznan, Poland)2025

Preoperative systemic inflammatory biomarkers can improve recurrence prediction of non-muscle invasive bladder cancer after endoscopic resection - a prospective observational study.

Klaudia Bardowska, Wojciech Krajewski, Anna Kołodziej, Katarzyna Kościelska-Kasprzak, Dorota Bartoszek, Marcelina Żabińska, Joanna Chorbińska, Tomasz Królicki, Magdalena Krajewska, Tomasz Szydełko and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Contemporary oncology (Poznan, Poland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Klaudia BardowskaDepartment of Nephrology and Transplantation Medicine, Wroclaw Medical University, Wrocław, Poland.
Wojciech KrajewskiUniversity Centre of Excellence in Urology, Wroclaw Medical University, Wrocław, Poland.
Anna KołodziejUniversity Centre of Excellence in Urology, Wroclaw Medical University, Wrocław, Poland.
Katarzyna Kościelska-KasprzakDepartment of Preclinical Sciences, Pharmacology and Medical Diagnostics, Faculty of Medicine, Wroclaw University of Science and Technology, Wrocław, Poland.
Dorota BartoszekDepartment of Preclinical Sciences, Pharmacology and Medical Diagnostics, Faculty of Medicine, Wroclaw University of Science and Technology, Wrocław, Poland.
Marcelina ŻabińskaDepartment of Preclinical Sciences, Pharmacology and Medical Diagnostics, Faculty of Medicine, Wroclaw University of Science and Technology, Wrocław, Poland.
Joanna ChorbińskaUniversity Centre of Excellence in Urology, Wroclaw Medical University, Wrocław, Poland.
Tomasz KrólickiDepartment of Anesthesiology and Intensive Care, Institute of Medical Sciences, University of Opole, Opole, Poland.
Magdalena KrajewskaDepartment of Non-Procedural Clinical Sciences, Faculty of Medicine, University of Science and Technology, Wrocław, Poland.
Tomasz SzydełkoUniversity Centre of Excellence in Urology, Wroclaw Medical University, Wrocław, Poland.
Dorota KamińskaDepartment of Non-Procedural Clinical Sciences, Faculty of Medicine, University of Science and Technology, Wrocław, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Non-muscle invasive bladder cancer (NMIBC) is one of the most commonly diagnosed urogenital types of cancer with a relatively favourable prognosis. Cystoscopy stands as the most significant diagnostic and monitoring procedure, however more accessible methods are needed for diagnosis and follow-up. Material and methods: A total of 285 pa-- tients with NMIBC were enrolled in this prospective study. Complete blood count (CBC) biomarkers and nutritional risk scores were evaluated for predicting cancer recurrence or progression after radical transurethral resection of bladder tumour (TURB). Additionally, the correlation between CBC biomarkers and European Organisation for Research and Treatment of Cancer (EORTC) risk scores was performed. A final study group with complete follow-up and dataset, comprised of 183. Results: After a 3-month follow-up period, 104 subjects experienced cancer recurrence or progression. A group of 79 patients were tumour free. The neutrophil-to-lymphocyte ratio (NLR) showed the highest area under the curve of 0.618 (95% CI: 0.536-0.699) with Conclusions: Complete blood count biomarkers can predict recurrence or progression of NMIBC after TURB, yet nutritional risk scores have demonstrated inadequate predictive value. Complete blood count biomarkers increase prognostic properties of EORTC risk score.

Indexed as

dNLR (derived neutrophil-to-lymphocyte ratio)European Organisation for Research and Treatment of Cancer (EORTC)GPS (Glasgow prognostic score)MLR (monocyte-to-lymphocyte ratio)NLR (neutrophil-to-lymphocyte ratio)non-muscle invasive bladder cancer (NMIBC)PLR (platelet-to-lymphocyte ratio)PNI (prognostic nutritional index)transurethral resection of bladder tumour (TURB)

Identifiers

PMID40620890
PMCPMC12224241

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.